Statin use and non-alcoholic steatohepatitis in at risk individuals

Journal of Hepatology

Volumn 63, Issue 3, 2015, Pages 705-712

  Dongiovanni, Paola ^a   Petta, Salvatore ^b   Mannisto, Ville ^c   Mancina, Rosellina Margherita ^d   Pipitone, Rosaria ^b   Karja, Vesa ^c   Maggioni, Marco ^a   Kakela, Pirjo ^c   Wiklund, Olov ^d   Mozzi, Enrico ^a   Grimaudo, Stefania ^b   Kaminska, Dorota ^e   Rametta, Raffaela ^f   Craxi, Antonio ^b   Fargion, Silvia ^a,f   Nobili, Valerio ^g   Romeo, Stefano ^d,h   Pihlajamaki, Jussi ^c,e   Valenti, Luca ^a,f  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c KUOPIO UNIVERSITY HOSPITAL   (Finland)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e UNIVERSITY OF EASTERN FINLAND   (Finland)

^f UNIVERSITY OF MILAN   (Italy)

^g BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^h UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Cholesterol; NASH; Non alcoholic fatty liver disease; Non alcoholic steatohepatitis; PNPLA3; Statin; Steatosis

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ADIPONUTRIN, HUMAN; MEMBRANE PROTEIN; TM6SF2 PROTEIN, HUMAN; TRIACYLGLYCEROL LIPASE;

ADULT; AGE; ALLELE; ARTICLE; BODY MASS; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG USE; FATTY LIVER; FEMALE; GENDER; GENE; GENETIC RISK; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; LIVER INJURY; LIVER PROTECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; PNPLA3 GENE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; AGED; BIOPSY; CHEMICALLY INDUCED; GENETICS; LIVER; MIDDLE AGED; PATHOLOGY; RISK; STATISTICAL MODEL;

ADULT; AGED; BIOPSY; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPASE; LIVER; LOGISTIC MODELS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; RISK;

EID: 84939268765     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2015.05.006     Document Type: Article

References (46)

1. P. Angulo Nonalcoholic fatty liver disease N Engl J Med 346 2002 1221 1231
2. J.D. Browning, L.S. Szczepaniak, R. Dobbins, P. Nuremberg, J.D. Horton, J.C. Cohen, and et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity Hepatology 40 2004 1387 1395
3. M. Blachier, H. Leleu, M. Peck-Radosavljevic, D.C. Valla, and F. Roudot-Thoraval The burden of liver disease in Europe: a review of available epidemiological data J Hepatol 58 2013 593 608
4. G. Marchesini, M. Brizi, A.M. Morselli-Labate, G. Bianchi, E. Bugianesi, A.J. McCullough, and et al. Association of nonalcoholic fatty liver disease with insulin resistance Am J Med 107 1999 450 455
5. E. Fabbrini, B.S. Mohammed, F. Magkos, K.M. Korenblat, B.W. Patterson, and S. Klein Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease Gastroenterology 134 2008 424 431
6. J.C. Cohen, J.D. Horton, and H.H. Hobbs Human fatty liver disease: old questions and new insights Science 332 2011 1519 1523
7. D.E. Kleiner, E.M. Brunt, M. Van Natta, C. Behling, M.J. Contos, O.W. Cummings, and et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease Hepatology 41 2005 1313 1321
8. C.P. Day From fat to inflammation Gastroenterology 130 2006 207 210
9. E. Bugianesi, N. Leone, E. Vanni, G. Marchesini, F. Brunello, P. Carucci, and et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma Gastroenterology 123 2002 134 140
10. Y.L. Liu, G. Patman, J. Leathart, A. Burt, C. Day, A. Daly, and et al. Carriage of PNPLA3 I148M is associated with increased risk of nonalcoholic fatty liver disease-associated hepatocellular carcinoma J Hepatol 58 2013 S516
11. P. Dongiovanni, Q.M. Anstee, and L. Valenti Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment Curr Pharm Des 19 2013 5219 5238
12. A.J. Sanyal, N. Chalasani, K.V. Kowdley, A. McCullough, A.M. Diehl, N.M. Bass, and et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis N Engl J Med 362 2010 1675 1685
13. D.M. Van Rooyen, C.Z. Larter, W.G. Haigh, M.M. Yeh, G. Ioannou, R. Kuver, and et al. Hepatic free cholesterol accumulates in obese, diabetic mice and causes nonalcoholic steatohepatitis Gastroenterology 141 2011 1393 1403 1403, e1391-e1395
14. G. Musso, R. Gambino, and M. Cassader Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis Prog Lipid Res 52 2013 175 191
15. H.K. Min, A. Kapoor, M. Fuchs, F. Mirshahi, H. Zhou, J. Maher, and et al. Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease Cell Metab 15 2012 665 674
16. M. Simonen, V. Mannisto, J. Leppanen, D. Kaminska, V. Karja, S. Venesmaa, and et al. Desmosterol in human nonalcoholic steatohepatitis Hepatology 58 2013 976 982
17. V.T. Mannisto, M. Simonen, P. Soininen, M. Tiainen, A.J. Kangas, D. Kaminska, and et al. Lipoprotein subclass metabolism in nonalcoholic steatohepatitis J Lipid Res 55 2014 2676 2684
18. M. Mari, F. Caballero, A. Colell, A. Morales, J. Caballeria, A. Fernandez, and et al. Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis Cell Metab 4 2006 185 198
19. A.L. Catapano, Z. Reiner, G. De Backer, I. Graham, M.R. Taskinen, O. Wiklund, and et al. ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) Atherosclerosis 217 2011 3 46
20. O. Wiklund, C. Pirazzi, and S. Romeo Monitoring of lipids, enzymes, and creatine kinase in patients on lipid-lowering drug therapy Curr Cardiol Rep 15 2013 397
21. C.E. de Keyser, E.M. Koehler, J.N. Schouten, L.E. Visser, A. Hofman, H.L. Janssen, and et al. Statin therapy is associated with a reduced risk of non-alcoholic fatty liver in overweight individuals Dig Liver Dis 46 2014 720 725
22. K.A. McGlynn, G.W. Divine, V.V. Sahasrabuddhe, L.S. Engel, A. VanSlooten, K. Wells, and et al. Statin use and risk of hepatocellular carcinoma in a U.S. population Cancer Epidemiol 38 2014 523 527
23. G. Musso, R. Gambino, M. Cassader, and G. Pagano Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity Ann Med 43 2012 617 649
24. M.J. Tikkanen, R. Fayyad, O. Faergeman, A.G. Olsson, C.C. Wun, R. Laskey, and et al. Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels Int J Cardiol 168 2013 3846 3852
25. G. Musso, M. Cassader, and R. Gambino Cholesterol-lowering therapy for the treatment of nonalcoholic fatty liver disease: an update Curr Opin Lipidol 22 2011 489 496
26. M. Ekstedt, L.E. Franzen, U.L. Mathiesen, M. Holmqvist, G. Bodemar, and S. Kechagias Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study J Hepatol 47 2007 135 141
27. A. Nelson, D.M. Torres, A.E. Morgan, C. Fincke, and S.A. Harrison A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: a randomized placebo-controlled trial J Clin Gastroenterol 43 2009 990 994
28. V.G. Athyros, K. Tziomalos, T.D. Gossios, T. Griva, P. Anagnostis, K. Kargiotis, and et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis Lancet 376 2010 1916 1922
29. T. Foster, M.J. Budoff, S. Saab, N. Ahmadi, C. Gordon, and A.D. Guerci Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial Am J Gastroenterol 106 2011 71 77
30. C. Pramfalk, P. Parini, U. Gustafsson, S. Sahlin, and M. Eriksson Effects of high-dose statin on the human hepatic expression of genes involved in carbohydrate and triglyceride metabolism J Intern Med 269 2011 333 339
31. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report Circulation 106 2002 3143 3421
32. N.J. Stone, J.G. Robinson, A.H. Lichtenstein, C.N. Bairey Merz, C.B. Blum, R.H. Eckel, and et al. ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Circulation 2014 2013 S1 S45
33. P. Dongiovanni, S. Petta, C. Maglio, A.L. Fracanzani, R. Pipitone, E. Mozzi, and et al. TM6SF2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease Hepatology 61 2015 506 514
34. S. Sookoian, and C.J. Pirola Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease Hepatology 53 2011 1883 1894
35. L. Laforest, T. Souchet, P. Moulin, C. Ritleng, G. Desamericq, P. Le Jeunne, and et al. Prevalence of low high-density lipoprotein cholesterol and hypertriglyceridaemia in patients treated with hypolipidaemic drugs Arch Cardiovasc Dis 102 2009 43 50
36. J. Trebicka, and R. Schierwagen Statins, Rho GTPases and KLF2: new mechanistic insight into liver fibrosis and portal hypertension Gut 2015 in press
37. P. Dongiovanni, B. Donati, R. Fares, R. Lombardi, R.M. Mancina, S. Romeo, and et al. PNPLA3 I148M polymorphism and progressive liver disease World J Gastroenterol 19 2013 6969 6978
38. S. He, C. McPhaul, J.Z. Li, R. Garuti, L. Kinch, N.V. Grishin, and et al. A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis J Biol Chem 285 2010 6706 6715
39. C. Pirazzi, M. Adiels, M.A. Burza, R.M. Mancina, M. Levin, M. Stahlman, and et al. Patatin-like phospholipase domain-containing 3 (PNPLA3) I148M (rs738409) affects hepatic VLDL secretion in humans and in vitro J Hepatol 57 2012 1257 1262
40. H. Ruhanen, J. Perttila, M. Holtta-Vuori, Y. Zhou, H. Yki-Jarvinen, E. Ikonen, and et al. PNPLA3 mediates hepatocyte triacylglycerol remodeling J Lipid Res 55 2014 739 746
41. R. Margherita Mancina, N. Matikainen, C. Maglio, S. Soderlund, N. Lundbom, A. Hakkarainen, and et al. Paradoxical dissociation between hepatic fat content and de novo lipogenesis due to PNPLA3 sequence variant J Clin Endocrinol Metab 2015 jc20144464
42. C. Pirazzi, L. Valenti, B.M. Motta, P. Pingitore, K. Hedfalk, R.M. Mancina, and et al. PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells Hum Mol Genet 23 2014 4077 4085
43. V. Nobili, G. Bedogni, B. Donati, A. Alisi, and L. Valenti The I148M variant of PNPLA3 reduces the response to docosahexaenoic acid in children with non-alcoholic fatty liver disease J Med Food 16 2013 957 960
44. C.S. Desai, S.S. Martin, and R.S. Blumenthal Non-cardiovascular effects associated with statins BMJ 349 2014 g3743
45. M. Ruscica, C. Macchi, B. Morlotti, C.R. Sirtori, and P. Magni Statin therapy and related risk of new-onset type 2 diabetes mellitus Eur J Intern Med 25 2014 401 406
46. G. Targher, C.P. Day, and E. Bonora Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease N Engl J Med 363 2010 1341 1350